帕金森病合并抑郁症的研究进展

摘要
图/表
参考文献(35)
相关文章 (15)

全文: PDF (0 KB) HTML (39 KB)
输出: BibTeX | EndNote (RIS)

摘要帕金森病（PD）是常见的神经系统退行性疾病之一，其临床表现包括运动症状和非运动症状。抑郁症是PD患者最常见的非运动症状。抑郁症可增加PD 患者的残疾率，降低PD 患者的生活质量，加重照护者负担。目前，PD 伴抑郁的诊治率仍较低。本文纳入30 余项国内外近年关于PD 伴抑郁的研究，发现PD 伴抑郁具有复杂的病理生理机制，在治疗方面，标准抗抑郁药物及非药物治疗均有一定效果，但各种治疗均存在一定不良反应，个体化治疗方案制定，是目前需要研究的方向。本文将在现有研究基础上，对帕金森病合并抑郁的发病因素、发病机制、治疗方式等方面进行综述，以期为帕金森病合并抑郁的预防及治疗方式的选择提供辅证。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	徐凤华
	罗海彦

关键词 ：帕金森病, 抑郁症, 发病机制, 治疗方式

Abstract：Parkinson′s disease(PD)is one of the common neurodegenerative diseases,whose clinical manifestations include motor symptoms and non-motor symptoms.Depression is the most common non-motor symptom in PD patients.Depression can increase the disability rate of PD patients,reduce the quality of life of PD patients,and increase the burden of caregivers.At present,the diagnosis and treatment rate of PD with depression is still low.More than 30 domestic and foreign studies on PD with depression in recent years were included in this paper,and it was found that PD with depression has a complex pathophysiological mechanism.In terms of treatment,both standard antidepressant drugs and non-drug therapy have certain effects,but all kinds of treatments have certain adverse reactions.Therefore,the development of individualized treatment plan is the direction of current research.Based on the existing studies,this paper will review the pathogenesis,pathogenesis and treatment of Parkinson′s disease with depression,in order to provide supporting evidence for the prevention and treatment of Parkinson′s disease with depression.

Key words： Parkinson&prime s disease Depressive disorder Pathogenesis Treatment.

通讯作者: 罗海彦（1965-），男，重庆人，博士，副主任医师/副教授，硕士研究生导师，研究方向：缺血性脑血管病介入治疗，帕金森病的诊治

作者简介: 徐凤华（1994-），女，云南临沧人，硕士，研究方向：脑血管病、帕金森病

引用本文:

徐凤华；罗海彦. 帕金森病合并抑郁症的研究进展[J]. 中国当代医药, 2021, 28(13): 29-32.
XU Feng-hua；LUO Hai-yan. Research progress of Parkinson′s disease complicated with depression. 中国当代医药, 2021, 28(13): 29-32.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2021/V28/I13/29

[1]	GBD 2016 Parkinson′s Disease Collaborators.Global，regional，and national burden of Parkinson′s disease，1990-2016：a systematic analysis for the Global Burden of Disease Study 2016[J].Lancet Neurol，2018，17（11）：939-953.
[2]	庞坚信，黄沛钰，王冬女，等.帕金森病不同运动障碍亚型的临床特征比较[J].中国现代医生，2020，58（16）：17-20，24.
[3]	蒋洋洋，张虹玮.帕金森病伴焦虑抑郁状态的中西医治疗进展[J].疑难病杂志，2018，17（9）：967-972.
[4]	Rana AQ，Qureshi ARM，Shamli Oghli Y，et al.Decreased sleep quality in Parkinson′s patients is associated with higher anxiety and depression prevalence and severity，and correlates with pain intensity and quality[J].Neurol Res，2018，40（8）：696-701.
[5]	Rana AQ，Qureshi ARM，Rahman N，et al.Disability from pain directly correlated with depression in Parkinson′s disease[J].Clin Neurol Neurosurg，2017，160：1-4.
[6]	Larsen JP，Dalen I，Pedersen KF，et al.The natural history of depressive symptoms in patients with incident Parkinson′s disease：a prospective cohort study[J].J Neurol，2017，264（12）：2401-2408.
[7]	Ng A，Chander RJ，Tan LC，et al.Influence of depression in mild Parkinson′s disease on longitudinal motor and cognitive function[J].Parkinsonism Relat Disord，2015，21（9）：1056-1060.
[8]	Ravina B，Camicioli R，Como PG，et al.The impact of depressive symptoms in early Parkinson disease[J].Neurology，2007，69（4）：342-347.
[9]	Jones JD，Butterfield LC，Song W，et al.Anxiety and depression are better correlates of Parkinson′s disease quality of life than apathy[J].J Neuropsychiatry Clin Neurosci，2015，27（3）：213-218.
[10]	Wu YH，Chen YH，Chang MH，et al.Depression in Parkinson′s disease：A case-control study[J].PLoS One，2018，13（2）：e0192050.
[11]	Leroi I，Harbishettar V，Andrews M，et all.Carer burden in apathy and impulse control disorders in Parkinson′s disease[J].Int J Geriatr Psychiatry，2012，27（2）：160-166.
[12]	Trnka R，Hasto J，Cabelkova I，et al.Amygdala and emotionality in Parkinson′s disease：An integrative review of the neuropsychological evidence[J].Neuro Endocrinol Lett，2018，39（2）：105-110.
[13]	Hanganu A，Bruneau MA，Degroot C，et al.Depressive symptoms in Parkinson′s disease correlate with cortical atrophy over time[J].Brain Cogn，2017，111：127-133.
[21]	Wang Y，Liu H，Du XD，et al.Association of low serum BDNF with depression in patients with Parkinson′s disease[J].Parkinsonism Relat Disord，2017，41：73-78.
[24]	Simons JA.Fluoxetine in Parkinson′s disease[J].Mov Disord，1996，11（5）：581-582.
[14]	Wu JY，Zhang Y，Wu WB，et al.Impaired long contact white matter fibers integrity is related to depression in Parkinson′s disease[J].CNS Neurosci Ther，2018，24（2）：108-114.
[15]	van Mierlo TJ，Chung C，Foncke EM，et al.Depressive symptoms in Parkinson′s disease are related to decreased hippocampus and amygdala volume[J].Mov Disord，2015，30（2）：245-252.
[16]	Kim YD，Jeong HS，Song IU，et al.Brain perfusion alterations in depressed patients with Parkinson′s disease[J].Ann Nucl Med，2016，30（10）：731-737.
[17]	Anders S，Sack B，Pohl A，et al.Compensatory premotor activity during affective face processing in subclinical carriers of a single mutant Parkin allele[J].Brain，2012，135（Pt 4）：1128-1140.
[18]	Remy P，Doder M，Lees A，et al.Depression in Parkinson′s disease：loss of dopamine and noradrenaline innervation in the limbic system[J].Brain，2005，128（Pt 6）：1314-1322.
[19]	Dalle E，Mabandla MV.Early Life Stress，Depression And Parkinson′s Disease：A New Approach[J].Mol Brain，2018，11（1）：18.
[20]	Wang XM，Zhang YG，Li AL，et al.Relationship between levels of inflammatory cytokines in the peripheral blood and the severity of depression and anxiety in patients with Parkinson′s disease[J].Eur Rev Med Pharmacol Sci，2016，20（18）：3853-3856.
[22]	Timmer MHM，van Beek M，Bloem BR，et al.What a neurologist should know about depression in Parkinson′s disease[J].Pract Neurol，2017，17（5）：359-368.
[23]	Bomasang -Layno E，Fadlon I，Murray AN，et al.Antidepressive treatments for Parkinson′s disease：A systematic review and meta-analysis[J].Parkinsonism Relat Disord，2015，21（8）：833-842.
[25]	Troeung L，Egan SJ，Gasson N.A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson′s disease[J].PloS one，2013，8（11）：e79510.
[26]	Richard IH，McDermott MP，Kurlan R，et al.A randomized，double-blind，placebo-controlled trial of antidepressants in Parkinson disease[J].Neurology，2012，78（16）：1229-1236.
[27]	Bonuccelli U，Meco G，Fabbrini G，et al.A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson′s disease[J].Expert Opin Pharmacother，2012，13（16）：2269-2280.
[28]	Korchounov A，Winter Y，Rossy W.Combined beneficial effect of rasagiline on motor function and depression in de novo PD[J].Clin Neuropharmacol，2012，35（3）：121-124.
[29]	Leggio GM，Salomone S，Bucolo C，et al.Dopamine D（3）receptor as a new pharmacological target for the treatment of depression[J].Eur J Pharmacol，2013，719（1-3）：25-33.
[30]	Barone P，Poewe W，Albrecht S，et al.Pramipexole for the treatment of depressive symptoms in patients with Parkinson′s disease：a randomised，double-blind，placebo-controlled trial[J].Lancet Neurol，2010，9（6）：573-580.
[31]	Borisovskaya A，Bryson WC，Buchholz J，et al.Electroconvulsive therapy for depression in Parkinson′s disease：systematic review of evidence and recommendations[J].Neurodegener Dis Manag，2016，6（2）：161-176.
[32]	Zhou L，Guo Z，Xing G，et al.Antidepressant effects of repetitive transcranial magnetic stimulation over prefrontal cortex of parkinson′s disease patients with depression：A meta-analysis[J].Front Psychiatry，2018，9：769.
[33]	Dobkin RD，Menza M，Allen LA，et al.Cognitive-behavioral therapy for depression in Parkinson′s disease：a randomized，controlled trial[J].Am J Psychiatry，2011，168（10）：1066-1074.
[34]	Calleo JS，Amspoker AB，Sarwar AI，et al.A pilot study of a cognitive-behavioral treatment for anxiety and depression in patients with Parkinson disease[J].J Geriatr Psychiatry Neurol，2015，28（3）：210-217.
[35]	Wu PL，Lee M，Huang TT.Effectiveness of physical activity on patients with depression and Parkinson′s disease：A systematic review[J].PLoS One，2017，12（7）：e0181515.